Linkedin

Latest press releases

View all

CellCentric strengthens Board and executive leadership with appointments of Paolo Pucci and Jason Cavalier 

8 September 2026 Press Release

CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma

6 May 2026 Press Release

CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma

31 March 2026 Press Release
Main Menu
Follow us on LinkedIn